Pricing Log in Create free account

Coherus Oncology, Inc. (CHRS) vs Retension Pharmaceuticals, Inc. (RTSN)

Coherus Oncology, Inc. and Retension Pharmaceuticals, Inc. are both Biotechnology companies. Retension Pharmaceuticals, Inc. is the larger, with a market value of $101.2M against $90.0M — 1.1× the size.

Valuation

Metric CHRS RTSN Biotechnology median
P/E n/m — 11.58
P/S 1.70 — 9.61
P/B 3.62 — 2.26
Price to free cash flow n/m — 26.41
EV/EBITDA n/m — 0.72
EV/Sales 4.39 — 9.43
Earnings yield (165.05%) — (32.28%)
Free cash flow yield (191.02%) — (22.27%)

Profitability

Metric CHRS RTSN Biotechnology median
Gross margin 69.81% — 68.81%
Operating margin (275.94%) — 0.00%
Net margin (253.43%) — 0.00%
Free cash flow margin (323.85%) — 0.00%
Return on equity (240.54%) — (50.30%)
Return on assets (39.54%) — (45.47%)
Return on invested capital 0.00% — 0.00%

Growth

Metric CHRS RTSN Biotechnology median
Revenue growth (TTM) 44.36% — 6.78%
EPS growth (last fiscal year) 472.00% — 29.88%
Revenue growth, 5-year CAGR (38.41%) — 9.75%
Net income growth, 5-year CAGR 4.91% — 0.00%

Health

Metric CHRS RTSN Biotechnology median
Debt to equity 2.08 — 0.00
Current ratio 1.51 — 4.74
Net debt to EBITDA 0.76 — 1.01

Dividend

Metric CHRS RTSN Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric CHRS RTSN Biotechnology median
Market cap 90.02m 101.23m 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack